Hosoon Choi

Dr. Hosoon Choi


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2024 in American Journal of Infection Control
Verified
Journal Article
Closed access
SGShantini D. Gamage
Shantini D. Gamage
CJChetan Jinadatha
Chetan Jinadatha
JRJr. Vincent Rizzo
Jr. Vincent Rizzo
PCPiyali Chatterjee
Piyali Chatterjee
HCHosoon Choi
Hosoon Choi
GRGary A. Roselle
Gary A. Roselle

2 April 2019 in Current Eye Research
Verified
Journal Article
Closed access
HCHosoon Choi
Hosoon Choi
CPCasie Phillips
Casie Phillips
JOJoo Youn Oh
Joo Youn Oh
LPLuke Potts
Luke Potts
RRRoxanne L. Reger
Roxanne L. Reger
SFSamuel Fulcher
Samuel Fulcher
PURPOSE: To investigate the therapeutic efficacy of tumor necrosis factor (TNF)-α stimulated gene/protein 6 (TSG-6) in a rat model of corneal alkali injury. METHODS: Corneal alkali injury was produced by placing an NaOH-soaked filter paper disk on the central cornea of the right eye of an anesthetized male Lewis (LEW/Crl) rat. Recombinant human TSG-6, or an equal volume of phosphate-buffered saline (PBS), was administered intravenously (IV), by anterior chamber (AC) injection, or as a topical drop. The affected eyes were photographed daily using a dissecting microscope and documented for clinical time course analysis of corneal opacification. Corneal tissue was excised at pre-determined therapeutic endpoints, with subsequent qRT-PCR or histological analyses. RESULTS: The continuous monitoring of corneal alkali injury progression revealed TSG-6 treatments do not show sufficient effectiveness in vivo regardless of IV injection, AC injection, or topical application. Corneal opacification and neovascularization were not diminished, and gene expression was not impacted by these treatments. However, both IV and AC administration of TSG-6 significantly suppressed pro-inflammatory cytokines compared to PBS-treated eyes. CONCLUSION: We conclude that the therapeutic potential of TSG-6 is insufficient in a rat corneal alkali injury model.

18 November 2019 in International Journal of Ophthalmology
Verified
Journal Article
Open access
LPLuke Potts
Luke Potts
CPCasie Phillips
Casie Phillips
MHMunok Hwang
Munok Hwang
SFSamuel Fulcher
Samuel Fulcher
HCHosoon Choi
Hosoon Choi
AIM: To study the effect of renalase peptide, RP-220, on cell viability of human corneal epithelial cells after alkali insult. METHODS: A dose-response relationship between cell viability and exposure to NaOH solution were characterized using cultured human corneal epithelial cells. Viability of corneal epithelial cells was determined using commercially available MTT and CyQUANT (R) assays. RESULTS: At a concentration of 6 mmol/L, insult with NaOH leads to reduced corneal epithelial cell viability by approximately 30%. This reduced viability was prevented by treating the cells after initial insult with the 20-amino acid renalase derived peptide (RP-220). CONCLUSION: RP-220 has a pro-survival role for RP-220 following alkaline insult to corneal epithelial cells.

22 February 2024 in Viruses
Verified
Journal Article
Open access
PDF file
HCHosoon Choi
Hosoon Choi
MHMunok Hwang
Munok Hwang
LCLisa Cornelius
Lisa Cornelius
DNDhammika Navarathna
Dhammika Navarathna
PCPiyali Chatterjee
Piyali Chatterjee
CJChetan Jinadatha
Chetan Jinadatha
The SARS-CoV-2 virus steadily evolves, and numerous antigenically distinct variants have emerged over the past three years. Tracking the evolution of the virus would help us understand the process that generates the diverse variants and predict the future evolutionary trajectory of SARS-CoV-2. Here, we report the evolutionary trajectory of a unique Omicron lineage identified during an outbreak investigation that occurred in a residence unit in the healthcare system. The new lineage had four distinct non-synonymous and two distinct synonymous mutations apart from its parental lineage. Since this lineage of virus was exclusively found during the outbreak, we were able to track the detailed evolutionary history of the entire lineage along the transmission path. Furthermore, we estimated the evolutionary rate of the SARS-CoV-2 Omicron variant from the analysis of the evolution of the lineage. This new Omicron sub-lineage acquired 3 mutations in a 12-day period, and the evolutionary rate was estimated as 3.05 × 10−3 subs/site/year. This study provides more insight into an ever-evolving virus.